The technique, called qBiCo, is described in the open-access journal Epigenetics Communications. It is a five-plex, TaqMan probe-based quantitative PCR assay that amplifies both single-copy genes and repetitive elements in bisulfite-converted DNA, the modified molecule that nearly every methylation experiment actually measures. From a single reaction, qBiCo estimates four critical parameters: the concentration of converted DNA, its degree of fragmentation, the global conversion efficiency, and the presence of inhibitors that could derail PCR amplification downstream.

The need for such a tool stems from an awkward chemical compromise. Bisulfite conversion works by treating DNA with sodium bisulfite at low pH and elevated temperature, converting unmethylated cytosines into uracils while leaving methylated cytosines untouched. Subsequent PCR replaces the uracils with thymines, so methylation patterns appear as C-to-T sequence variants readable by microarrays, pyrosequencing or massively parallel sequencing. But the same aggressive conditions that perform the conversion also attack the DNA itself. Sodium bisulfite causes depyrimidination and generates abasic sites prone to strand breaks, meaning the treated molecule is fragmented, mostly single-stranded and contaminated with carryover chemicals. Choose gentler conditions and the conversion becomes incomplete, leading to overestimated methylation and misinterpreted data. Choose harsher conditions and the DNA shatters beyond use.

Despite these well-known hazards, most epigenetics researchers have relied on manufacturer promises of greater than 99 percent conversion efficiency, at least 80 percent recovery and eluted fragments up to 2,000 base pairs long. Existing assessment approaches have been piecemeal: Nanodrop spectrophotometry, Qubit fluorometry and Bioanalyzer fragment analysis were never designed for the peculiar, hybrid single- and double-stranded nature of bisulfite-converted DNA. Earlier targeted assays, such as one developed by Ehrich and colleagues, measured fragmentation at increasing incubation temperatures but said nothing about conversion efficiency, while single-locus approaches risked severe bias. None offered a global picture in one test.

The Rotterdam team, led by Athina Vidaki together with Faidra Karkala and colleagues, designed qBiCo around two carefully chosen target classes. A short fragment of the single-copy hTERT gene reports converted DNA concentration, while a longer fragment of the same gene provides a fragmentation index. Two assays target the genomic and converted versions of LINE1, a repetitive element that constitutes roughly 17 percent of the human genome, allowing conversion efficiency to be measured across hundreds of genomic copies rather than a single locus. Because each LINE1 probe interrogates five cytosines across approximately 180 to 200 genomic regions, the efficiency measure is far more representative than comparable systems, such as BisQuE, which relies on a single cytosine in one gene intron. A fifth assay, a spiked-in artificial fragment, acts as an internal positive control flagging PCR inhibition.

Because no reliable standard exists for quantifying converted DNA, the team built synthetic DNA fragments, or gBlocks, mimicking the exact sequences their assays produce, mixed in ratios that resemble natural human converted DNA. Validation showed PCR efficiencies between 90 and 99 percent, linear detection down to picogram quantities, and striking robustness: conversion efficiency readings held steady even in the presence of extremely high levels of the PCR inhibitor hematin. Only artificial DNA degradation, induced by even one minute of UV exposure, meaningfully disturbed the readings.

The real drama came when the researchers applied qBiCo to ten commercial bisulfite conversion kits across DNA inputs ranging from 200 nanograms down to 1 nanogram. Recovery of converted DNA ranged from a sobering 8.5 to 100 percent, and conversion efficiencies from 78 to 99.9 percent, a spread that flatly contradicts the universal promises on the packaging. One kit failed systematically, producing conversion rates as low as 2 percent. Others lost more than 70 percent of the input DNA, while a handful, notably kits from Diagenode, Sigma Aldrich and Qiagen, maintained conversion efficiency above 95 percent even at the lowest inputs. Fragmentation proved pervasive: even with the best-performing kit, the intact portion of DNA fragments at least 235 base pairs long was no more than 50 to 60 percent of the sample, and longer fragments became undetectable at 10-nanogram inputs.

These results echo and extend earlier warnings. A 2018 study by Kint and colleagues had already reported kit recoveries ranging from 26.6 to 88.3 percent using a cumbersome multi-method approach that consumed precious sample. Even the inventor of bisulfite conversion, Hikoya Hayatsu, cautioned in 2008 that available methylation data needed careful re-examination and that a scientifically sound, assured methodology should be established as soon as possible. The qBiCo team argues that the field has, in effect, been running on assumption, and that no bisulfite-converted-DNA-specific method existed until now to hold the process accountable.

Determined to turn the assay into a practical tool, the researchers built an improved prototype, qBiCo-v2. They replaced the weakest assay, a long hTERT fragment, with a 222-base-pair target from the TPT1 gene, halved the reaction volume to 10 microliters, refined the synthetic standard using data from sixteen different conversion kits, and developed a semi-automated spreadsheet pipeline that calculates all four indices directly from raw qPCR output. Crucially, they transferred the method to six qPCR platforms from three major manufacturers, BioRad, Thermo Fisher Scientific and Qiagen, and validated it on each, finding comparable quantification cycles across instruments and establishing a detection limit of 150 picograms of input DNA.

The implications reach well beyond the bench. DNA methylation biomarkers are moving toward clinical implementation in cancer detection, ageing research and forensic science, settings where standardization is paramount and where scarce or degraded samples, such as cell-free tumor DNA or crime-scene traces, make every molecule count. The authors call on epigenetics researchers to shift from assuming their conversion kits work to measuring them empirically, integrating qBiCo as a routine quality-control step regardless of the downstream analysis. If they succeed, a reaction that has quietly shaped two decades of epigenetic data may finally get the scrutiny it has always needed, and the methylation maps of the future could rest on far firmer ground.

Subject of Research: Quality control of bisulfite-converted DNA methylation analysis using quantitative PCR

Article Title: qBiCo: a method to assess global DNA conversion performance in epigenetics via single-copy genes and repetitive elements

Article References: Karkala, F., Simons, R. B., Claessens, F., Kalamara, V., Kayser, M., & Vidaki, A. (2025). qBiCo: a method to assess global DNA conversion performance in epigenetics via single-copy genes and repetitive elements. Epigenetics Communications, 5(1), Article 2. https://doi.org/10.1186/s43682-025-00033-3

Image Credits: AI Generated

DOI: 10.1186/s43682-025-00033-3

Keywords: DNA methylation, bisulfite conversion, epigenetics, qPCR, quality control, LINE1, hTERT, DNA fragmentation, biomarkers, forensics, kit validation, standardization